Nexalin Technology

6 articles about Nexalin Technology

• Nexalin Technology Provides 2022 Year-End Business Update

  3/27/2023

  Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today provided a business update for the year ended December 31, 2022.

• Nexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory

  1/24/2023

  Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) , today announced the appointment of Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory.

• Nexalin Technology, Inc. Announces Closing of $9.6 Million Initial Public Offering

  9/20/2022

  Nexalin Technology, Inc. (the “Company” or “Nexalin”) today announced the closing of its previously announced initial public offering of 2,315,000 units consisting of 2,315,000 shares of its common stock and 2,315,000 accompanying warrants to purchase 2,315,000 shares of common stock.

• Nexalin Technology, Inc. Announces Pricing of $9.6 Million Initial Public Offering

  9/16/2022

  Nexalin Technology, Inc. (the “Company” or “Nexalin”) today announced the pricing of its initial public offering of 2,315,000 units consisting of  2,315,000 shares of its Common Stock and  2,315,000 accompanying warrants to purchase up to  2,315,000 shares of common stock.

• Nexalin Technology Demonstrates Success in the Treatment of Depression

  11/9/2017

  Nexalin Technology is pleased to announce the initiation of clinical trials designed by the University of Pennsylvania to investigate the effectiveness of the Nexalin transcranial stimulation (TACS) for major depressive disorder.

• Nexalin Technology May Be the Future of Opiate Addiction Treatment

  11/7/2017

  Nexalin has initiated pilot trials in addiction treatment centers around the United States for the treatment of opiate addiction.